Blood-brain barrier dysfunction and cerebral small vessel disease (arteriolosclerosis) in brains of older people

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 11, 2014, Pages 1026-1033

  Bridges, Leslie R ^a,b   Andoh, Joycelyn ^a   Lawrence, Andrew J ^a,e   Khoong, Cheryl H L ^a   Poon, Wayne W ^f   Esiri, Margaret M ^c,d   Markus, Hugh S ^a,e   Hainsworth, Atticus H ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arteriolosclerosis; Blood brain barrier; Dementia; Fibrinogen; Leukoaraiosis; Small vessel disease

Indexed keywords

FIBRINOGEN; IMMUNOGLOBULIN G;

AGED; AGING; ALZHEIMER DISEASE; ANTIBODY LABELING; ARTERIOLOSCLEROSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; EXTRAVASATION; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NEUROPATHOLOGY; QUANTITATIVE ANALYSIS; VASCULAR AMYLOIDOSIS; WHITE MATTER; BRAIN; CEREBROVASCULAR DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; SINGLE BLIND PROCEDURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARTERIOLOSCLEROSIS; BLOOD-BRAIN BARRIER; BRAIN; CEREBRAL SMALL VESSEL DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD;

EID: 84916224368     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000124     Document Type: Article

References (60)

1. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13-25
2. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178-201
3. Cserr HF, DePasquale M, Patlak CS. Regulation of brain water and electrolytes during acute hyperosmolality in rats. Am J Physiol 1987;253: F522-29
4. Fraser PA, Dallas AD. Permeability of disrupted cerebral microvessels in the frog. J Physiol 1993;461:619-32
5. Kuntz M, Mysiorek C, Petrault O, et al. Stroke-induced brain parenchymal injury drives blood-brain barrier early leakage kinetics: a combined in vivo/in vitro study. J Cereb Blood Flow Metab 2014;34:95-107
6. Argaw AT, Asp L, Zhang J, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012;122:2454-68
7. Argaw AT, Zhang Y, Snyder BJ, et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 2006;177:5574-84
8. Seo JH, Miyamoto N, Hayakawa K, et al. Oligodendrocyte precursors induce early blood-brain barrier opening after white matter injury. J Clin Invest 2013;123:782-86
9. Nag S, Venugopalan R, Stewart DJ. Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown. Acta Neuropathol 2007;114:459-69
10. Starr JM, Wardlaw J, Ferguson K, et al. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003;74:70-76
11. Taheri S, Gasparovic C, Huisa BN, et al. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 2011;42:2158-63
12. Topakian R, Barrick TR, Howe FA, et al. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 2010;81: 192-97
13. Simpson JE, Ince PG, Higham CE, et al. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol Appl Neurobiol 2007;33:670-83
14. Tomimoto H, Akiguchi I, Suenaga T, et al. Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke 1996;27:2069-74
15. Utter S, Tamboli IY, Walter J, et al. Cerebral small vessel diseaseY induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. J Neuropathol Exp Neurol 2008;67:842-56
16. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008;71:804-11
17. Alafuzoff I, Adolfsson R, Grundke-Iqbal I, et al. Perivascular deposits of serum proteins in cerebral cortex in vascular dementia. Acta Neuropathol 1985;66:292-98
18. Lammie GA, Brannan F, Wardlaw JM. Incomplete lacunar infarction (Type Ib lacunes). Acta Neuropathol (Berl) 1998; 96:163-71
19. Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007;28:977-86
20. Viggars AP, Wharton SB, Simpson JE, et al. Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort. Neurosci Lett 2011;505:25-30
21. Kirk J, Plumb J, Mirakhur M, et al. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003;201:319-27
22. Leech S, Kirk J, Plumb J, et al. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007;33:86-98
23. van Horssen J, Brink BP, de Vries HE, et al. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007; 66:321-28
24. Gveric D, Herrera B, Petzold A, et al. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003; 126:1590-98
25. Dallasta LM, Pisarov LA, Esplen JE, et al. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999;155:1915-27
26. Brown H, Hien TT, Day N, et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999; 25:331-40
27. Liu JY, Thom M, Catarino CB, et al. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012;135: 3115-33
28. Hultman K, Strickland S, Norris EH. The APOE varepsilon4/varepsilon4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J Cereb Blood Flow Metab 2013;33:1251-58
29. Berzin TM, Zipser BD, Rafii MS, et al. Agrin and microvascular damage in Alzheimer's disease. Neurobiol Aging 2000;21:349-55
30. Sengillo JD, Winkler EA, Walker CT, et al. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 2013;23:303-10
31. Tomimoto H, Akiguchi I, Wakita H, et al. Regressive changes of astroglia in white matter lesions in cerebrovascular disease and Alzheimer's disease patients. Acta Neuropathol 1997;94:146-52
32. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol 1968;12:1-15
33. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002;12:358-70
34. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689-701
35. Schmidt R, Schmidt H, Haybaeck J, et al. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-85
36. Giwa MO, Williams J, Elderfield K, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology 2012;78: 167-74
37. Wardlaw JM, Sandercock PA, Dennis MS, et al. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003;34:806-12
38. Wardlaw JM, Doubal FN, Valdes-Hernandez M, et al. Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease. Stroke 2013;44:525-27
39. Smallwood A, Oulhaj A, Joachim C, et al. Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: a pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathol Appl Neurobiol 2012;38:337-43
40. Mendes Ribeiro HK, Barnetson LP, Hogervorst E, et al. A new visual rating scale for white matter low attenuation on CT. Eur Neurol 2001; 45:140-44
41. Hogervorst E, Ribeiro HM, Molyneux A, et al. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002;59: 787-93
42. Hainsworth AH, Allsopp RC, Jim A, et al. Death-associated protein kinase (DAPK1) in cerebral cortex of late-onset Alzheimer's disease patients and aged controls. Neuropathol Appl Neurobiol 2010;36:17-24
43. Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749-53
44. Chalmers K, Wilcock GK, Love S. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 2003;29:231-38
45. Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature 2010;468:557-61
46. Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012;485:512-16
47. Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012;3:1227
48. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012;34:43-62
49. Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012;11:597-604
50. Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets 2009;8:31-49
51. Boche D, Denham N, Holmes C, et al. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 2010;120:369-84
52. Greenberg SM, Al-Shahi SR, Biessels GJ, et al. Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol 2014; 13:419-28
53. Abuqayyas L, Balthasar JP. Investigation of the role of FcgammaR and FcRn in mAb distribution to the brain. Mol Pharm 2013;10:1505-13
54. Tabrizi P, Wang L, Seeds N, et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 1999;19:2801-6
55. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007;204:1999-2008
56. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular diseaseVsystematic review and meta-analysis. Neurobiol Aging 2009; 30:337-52
57. Wardlaw JM, Doubal F, Armitage P, et al. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann Neurol 2009;65: 194-202
58. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003;161: 653-60
59. Nishitsuji K, Hosono T, Nakamura T, et al. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 2011;286:17536-42
60. Hartz AM, Bauer B, Soldner EL, et al. Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 2012; 43:514-23